OBSV News and Press, ObsEva SA From 12/10/21

- S ymposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- - 52-Week Da ta from the Phase 3 PRIMROSE stud ies ...

Check These Biotech Penny Stocks Out For Your Watchlist Right Now Finding the best biotech penny stocks to buy is all about understanding what catalysts are on the horizon. While most penny stocks are speculative, and therefore trade heavily on news and events, biotech stocks are es...

GENEVA, Switzerland December 2 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced a symposium and three oral presentations on linzagoli...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It seems that the definition of penny stocks may be changing again. I say that because, in researching this article, I came across a screening tool that defined penny stocks as those trading for $10 or less . That was a f...

Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, traders! We’re getting right into the week with a look at the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com Acquisition news, FDA acceptance, earnings report...

Obseva (NASDAQ:OBSV) announces that the New Drug Application (NDA) for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the U.S. FDA. The submission is based on data from the two Phase 3 PRIMROSE ...

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune syste...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In order to find penny stocks that have a strong likelihood of booking profits within the next six weeks, investors are going to have to accept an extra measure of risk. That’s because there’s inherent risk i...

CFRA has upgraded shares of Syneos Health (SYNH +2.9%) to buy from hold citing a "strong demand environment for CROs with its robust pipeline." The firm has a $108 price target (8% upside). Analyst Sel Hardy writes that Syneos' recent acquisitions of StudyKIK and RxDataScience allow the compa...